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Abstract
Background: Previous studies have shown that beta amyloid (Aβ) peptide triggers the activation
of several signal transduction cascades in the hippocampus, including the extracellular signal-
regulated kinase (ERK) cascade. In this study we sought to characterize the cellular localization of
phosphorylated, active ERK in organotypic hippocampal cultures after acute exposure to either Aβ
(1-42) or nicotine.
Results: We observed that Aβ and nicotine increased the levels of active ERK in distinct cellular
localizations. We also examined whether phospho-ERK was regulated by redox signaling
mechanisms and found that increases in active ERK induced by Aβ and nicotine were blocked by
inhibitors of NADPH oxidase.
Conclusion: Our findings indicate that NADPH oxidase-dependent redox signaling is required for
Aβ-induced activation of ERK, and suggest a similar mechanism may occur during early stages of
Alzheimer's disease.
Background
Beta amyloid (Aβ) peptide is typically considered neuro-
toxic as it is present in high levels and accumulates in
plaques in the brain of Alzheimer's disease (AD) patients
[1]. However, Aβ also is present in the normal brain at
lower levels than in the disease state, suggesting that it has
normal cellular and physiological functions [2]. There-
fore, studies of the impact of exposure of the brain to Aβ
could provide important information with respect to its
role during both physiological and pathophysiological
processes. It has been demonstrated that acute treatment
of organotypic hippocampal cultures with nanomolar
concentrations of oligomeric Aβ (1-42) leads to the acti-
vation of extracellular signal-regulated kinase (ERK) via
the alpha 7 nicotinic acetylcholine receptor (α 7nAChR)
[3,4]. This signaling cascade involves an increase in cal-
cium and activation of ERK mediated by phosphoi-
nositide-3 kinase (PI3K), which is followed by increases
in CREB phosphorylation [3-6]. Similar to Aβ, nicotine
treatment causes ERK activation via α 7nAChR and
requires PI3K. However, protein kinase A (PKA) appears
to be an upstream regulator of ERK activation after nico-
tine treatment, but not after Aβ treatment [3]. The activa-
tion of different signaling cascades by Aβ and nicotine
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and/or localization by these molecules. In this study we
sought to characterize the cellular localization of the Aβ-
and nicotine-induced increases in active ERK in area CA1
of hippocampal organotypic cultures.
Reactive oxygen species (ROS) typically are characterized
as molecules involved in neurotoxicity and neurodegener-
ation [7]. However, substantial evidence suggests that
ROS also function as small messenger molecules that are
normal components of signal transduction cascades
required for physiological processes such as synaptic plas-
ticity, learning, and memory [8]. Because it is known that
Aβ peptides can produce ROS, it is important to identify
the source of the ROS production, as well as downstream
effectors of ROS. NADPH oxidase is particularly intriguing
as a possible source of ROS produced by Aβ peptides.
NADPH oxidase is a tightly regulated, multiprotein
enzyme that produces large quantities of the ROS super-
oxide that has been well characterized in phagocytic cells
[9]. The active oxidase is made up of several protein com-
ponents, including two membrane proteins, gp91phox and
p22phox (also known as cytochrome b558), and three
cytosolic proteins, p47phox, p67phox, and the small GTP-
binding protein Rac. Upon stimulation, the cytosolic pro-
teins translocate to the membrane to form a complex with
cytochrome b558, which results in enzymatic activation
and production of superoxide [10,11]. In recent years,
NADPH oxidase and NADPH oxidase-like enzymes
(NOX) have been described in non-phagocytic cells
[12,13]. For example, NADPH oxidase has been observed
in peripheral neurons [14,15], cerebral cortical neurons
[16,17], and cerebellar Purkinje neurons [18] among oth-
ers. NADPH oxidase also is present in the hippocampus,
including pyramidal neurons in area CA1 [19,20]. Super-
oxide produced by NADPH oxidase predominately has
been studied with respect to neurotoxicity [15,21], but
there also is evidence that superoxide is required for hip-
pocampal long-term potentiation and hippocampus-
dependent memory [22-25]. Therefore, NADPH oxidase
could play an important role not only in disease condi-
tions, but also during normal neuronal function. Interest-
ingly, it has been demonstrated that in brains of AD
patients there is an increase in the expression of NADPH
oxidase proteins [26] and that AD model mice lacking
gp91phox do not develop oxidative stress, cerebrovascular
dysfunction, or behavioral deficits [27]. Furthermore, in
vitro studies using cortical neurons have demonstrated an
involvement of NADPH oxidase in response to Aβ (1-42)
stimulation [28]. These observations suggest that NADPH
oxidase could contribute to the oxidative stress associated
with AD, and also implicate it in regulating signal trans-
duction cascades under more physiological conditions. In
this study we sought to investigate whether Aβ peptide
regulates the ERK signaling cascade via NADPH oxidase in
hippocampal organotypic cultures.
Results
Differential cellular expression of ERK after Aβ- and 
nicotine-treatments
It has been demonstrated that both Aβ peptide and nico-
tine induce the activation of ERK in organotypic hippoc-
ampal cultures [4]. To better understand Aβ- and nicotine-
induced activation of ERK, we determined the cellular
localization of the active form of ERK (phospho-ERK)
after each treatment. Using antibodies against several cell
markers we observed differences in the cellular localiza-
tion of active ERK immunoreactivity in Aβ- and nicotine-
treated organotypic cultures (Figure 1). Treatment with Aβ
resulted in the activation of ERK in both neuronal cell
bodies and dendrites, as phospho-ERK immunoreactivity
was present in stratum pyramidale and stratum radiatum
of hippocampal area CA1 (Figure 1A and 1B). In contrast,
treatment of the organotypic cultures with nicotine did
not appear to activate ERK in the cell bodies of the pyram-
idal neurons, but rather in stratum radiatum (Figure 1A
and 1B). We also treated hippocampal slices with a higher
concentration of nicotine (500 μM) and found the pattern
of ERK activation was similar and not localized to the cell
bodies (data not shown). Because stratum radiatum
includes pyramidal neuron dendrites and interneurons,
we also used antibodies against GABAergic interneurons
to examine whether they expressed active ERK. Aβ- and
nicotine-induced increases in active ERK in stratum radia-
tum did not appear to co-localize with the GABAergic
marker GAD67, as the staining did not show a punctuate
appearance (Figure 1C). Neither Aβ nor nicotine appeared
to cause activation of active ERK in either astrocytes (Fig-
ure 1D) or microglia (Figure 1E). These observations sug-
gest that the activation of ERK after either Aβ or nicotine
treatment is restricted to neurons and is not present in
glial cells. Moreover, these stimuli appear to trigger activa-
tion of ERK in distinct neuronal compartments.
Aβ peptide-induced activation of ERK is blocked by the 
NADPH oxidase inhibitors apocynin and DPI
In order to investigate whether the Aβ-induced activation
of ERK was mediated by NADPH oxidase, we treated orga-
notypic cultures with Aβ in the presence or absence of
apocynin (100 μM) and diphenyleneiodomium (10 μM;
DPI). These two compounds inhibit NADPH oxidase by
blocking distinct sites: apocynin blocks the p47phox subu-
nit and DPI blocks the gp91phox subunit. Western blot
analysis indicated that treatment of hippocampal organo-
tyopic cultures with Aβ caused an increase in ERK phos-
phorylation compared to vehicle treatment (Figure 2A)
supporting previous observations [3,4]. Furthermore, we
found that treatment with Aβ in the presence of apocynin
failed to increase ERK phosphorylation above control lev-
els (Figure 2A). Similar results were observed when hip-
pocampal organotypic cultures were exposed to Aβ in the
presence of another NADPH oxidase inhibitor, DPI (Fig-
ure 2B). Immunocytochemical analysis also demon-Page 2 of 10
(page number not for citation purposes)
Molecular Brain 2009, 2:31 http://www.molecularbrain.com/content/2/1/31
Page 3 of 10
(page number not for citation purposes)
Aβ- and nicotine-induced activation of ERK in cultured hippocampal slicesFigure 1
Aβ- and nicotine-induced activation of ERK in cultured hippocampal slices. Hippocampal slice cultures were treated 
with culture media, media containing Aβ (100 nM), or media containing nicotine (500 nM) for either 5 min or 10 min, respec-
tively. Confocal images of hippocampal area CA1 were obtained from slices that were double labeled using antibodies specific 
for phospho-ERK (red) and A) the neuronal marker NeuN (green), B) the dendritic marker MAP2 (green), C) a marker for 
GABAergic interneurons GAD67 (green), D) the astrocytic marker GFAP (green), and E) the microglial marker IB4 (green). 
Dual labeling is indicated by yellow/orange. All the images were taken with a 20× objective and inserts represent higher magni-
fications (optical zoom 3.0). The scale bars are the same in all images and represent 20 μm and 10 μm, respectively.
Molecular Brain 2009, 2:31 http://www.molecularbrain.com/content/2/1/31strated that increases in active ERK in both pyramidal
neuron cell bodies and dendrites induced by Aβ treatment
were blocked by apocynin (Figure 2C). These observa-
tions suggest that superoxide produced by the NADPH
oxidase is necessary for the Aβ-induced neuronal activa-
tion of ERK.
Nicotine-induced activation of ERK is blocked by the 
NADPH oxidase inhibitors apocynin and DPI
Because Aβ peptides have been shown to interact with nic-
otinic receptors to trigger the activation of ERK [4], we
asked whether nicotine-induced activation of ERK also
requires NADPH oxidase. Western blot analysis demon-
strated that treatment of hippocampal organotyopic cul-
tures with nicotine caused an increase in phospho-ERK
that was blocked by apocynin (Figure 3A). Similar results
were observed when hippocampal organotypic cultures
were exposed to nicotine in the presence of DPI (Figure
3B). Immunocytochemical analysis also demonstrated
that increases in active ERK in the stratum radiatum area
induced by nicotine treatment were blocked by apocynin
(Figure 3C). These observations suggest that superoxide
produced by NADPH oxidase is necessary for the nicotine-
induced neuronal activation of ERK.
Aβ peptide-induced activation of ERK is blocked by the NADPH oxidase inhibitors apocynin and DPIFigure 2
Aβ peptide-induced activation of ERK is blocked by the NADPH oxidase inhibitors apocynin and DPI. Hippoc-
ampal slice cultures were pretreated for either 25 or 55 min with media in the presence or absence of either 100 μM apocynin 
(A) or 10 μM DPI (B), followed by incubation with Aβ (100 nM, 5 min). A, B) Western blots. Phospho-ERK immunoreactivity 
was normalized to total ERK and expressed as percent of control. Data represent the mean ± SEM; n = 7-10; *p < 0.01; **p < 
0.001; #p < 0.05. C) Immunocytochemistry. Confocal images of hippocampal area CA1 were obtained from slices that were 
double labeled using antibodies specific for phospho-ERK (red) and the neuronal marker NeuN (green). Dual labeling is indi-
cated by yellow/orange. Images were taken with a 20× objective and the scale bar represents 20 μm.Page 4 of 10
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activation of ERK
It has been previously demonstrated that Aβ interacts with
nicotinic acetylcholine receptors [3-6,29,30]. In particu-
lar, there is evidence indicating that micromolar concen-
trations of methyllycaconitine (MLA) blocks Aβ-induced
increases in ERK phophorylation in hippocampal organo-
typic slices [4]. It also has been demonstrated that MLA is
more selective for the α7 subunit of nAChRs at nanomo-
lar concentrations [31,32]. Western blot analysis demon-
strated that in the presence of nanomolar concentrations
of MLA, Aβ failed to cause a significant increase in the lev-
els of phospho-ERK compared to control (Figure 4A).
Immunocytochemical examination confirmed that the
Aβ-induced increase in phospho-ERK immunoreactivity
was reduced by MLA in both the pyramidal cell bodies
and dendrites (Figure 4B). Similarly, the nicotine-induced
increase in active ERK was inhibited in the presence of
MLA (Figure 4C). The increases in active ERK in the den-
dritic region induced by nicotine treatment also were
blocked by MLA treatment (Figure 4D). Taken together,
these findings support previous observations demonstrat-
ing a role for α7nAChR in regulating ERK activation after
Aβ and nicotine treatments. Although there was not a sig-
nificant increase in ERK activation when Aβ was added to
slices in the presence of nanomolar concentrations of
MLA, there was a trend for increased active ERK. This sug-
gests the possibility that Aβ impacts other nicotinic recep-
tors and signaling pathways to trigger activation of ERK.
Nicotine-induced activation of ERK is blocked by the NADPH oxidase inhibitors apocynin and DPIFigure 3
Nicotine-induced activation of ERK is blocked by the NADPH oxidase inhibitors apocynin and DPI. Hippocampal 
slice cultures were pretreated for 25 or 55 min with media in the presence or absence of either 100 μM apocynin (A) or 10 
μM DPI (B), followed by incubation with nicotine (500 nM, 10 min). A, B) Western blots. Phospho-ERK immunoreactivity was 
normalized to total ERK and expressed as percent of control. Data represent the mean ± SEM; n = 6-8; * p < 0.01, ** p < 
0.001. C) Immunocytochemistry. Confocal images of hippocampal area CA1 were obtained from slices that were double 
labeled using antibodies specific for phospho-ERK (red) and the neuronal marker NeuN (green). Dual labeling is indicated by 
yellow/orange. Images were taken with a 20× objective and the scale bar represents 20 μm.Page 5 of 10
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Aβ- and nicotine-induced activation of ERK is decreased by the α7nAChR inhibitor MLAFigure 4
Aβ- and nicotine-induced activation of ERK is decreased by the α7nAChR inhibitor MLA. Hippocampal slice cul-
tures were pretreated for 30 min with media in the presence or absence of MLA (10 nM) followed by incubation with Aβ (100 
nM, 5 min). A) Western blots. Phospho-ERK immunoreactivity was normalized to total ERK and expressed as percent of con-
trol. Data represent the mean ± SEM. n = 3-6; *p < 0.01. B) Immunocytochemistry. Confocal images were obtained from slices 
that were double labeled using antibodies specific for phospho-ERK (red) and the neuronal marker NeuN (green). Dual labeling 
is indicated by yellow/orange. Hippocampal slice cultures were pretreated for 30 min with media in the presence or absence of 
MLA (10 nM) followed by incubation with nicotine (500 nM, 5 min). C) Western blots. Phospho-ERK immunoreactivity was 
normalized to total ERK and expressed as percent of control. Data represent the mean ± SEM. n = 3-6, **p < 0.001. D) Immu-
nocytochemistry. Confocal images were obtained from slices that were double labeled using antibodies specific for phospho-
ERK (red) and the neuronal marker NeuN (green). Dual labeling is indicated by yellow/orange. Images were taken with a 20× 
objective and the scale bar represents 50 μm.
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Acute treatments of organotypic hippocampal cultures
with either Aβ or nicotine have been found to increase
ERK phosphorylation [3,4]. Herein, we have expanded on
those previous observations by using immunocytochem-
istry and have determined that the increase in ERK phos-
phorylation after Aβ treatment was localized to the cell
soma and dendrites of hippocampal CA1 neurons (Figure
1). Interestingly, our data indicate that nicotine treatment
induced ERK phosphorylation only in the dendritic com-
partment because the cell soma lacked enhanced phos-
pho-ERK immunoreactivity. The differences in the
localization of phospho-ERK activation following Aβ and
nicotine suggest that ERK activation is mediated by differ-
ent upstream signaling modules. Consistent with this
observation, it has been shown that both Aβ and nicotine
trigger the activation of ERK, but by using distinct inter-
mediate kinases [3]. More studies are necessary to specifi-
cally address the implications of this differential
compartmentalization of ERK phosphorylation after these
two treatments.
Importantly, we also observed that acute treatment with
nanomolar concentrations of Aβ induced the activation of
ERK in neurons, but not glial cells (Figure 1), as we did
not observe dual staining for phospho-ERK with markers
for either astrocytes or microglia. Similarly, nicotine treat-
ment showed no evidence of active ERK immunoreactivity
in glia cells (Figure 1). It previously was observed that Aβ
treatment can cause increases in active ERK in glia cells;
however, these increases in active ERK were after chronic
exposure to Aβ, suggesting that the cells were responding
to neurotoxic events [33-35]. In addition, chronic treat-
ment with nanomolar concentrations of either mono-
meric or oligomeric Aβ, as well as higher concentrations
(micromolar) of fibrillar Aβ, are typically associated with
ERK activation leading to neurotoxicity [3,36]. Further-
more, it has been demonstrated that in early stages of AD
there is a transient increase in active ERK in astrocytes that
might represent a response to axonal damage and presyn-
aptic loss [37]. All together, these findings suggest a sce-
nario where low concentrations of Aβ induces the
physiological activation of ERK in neurons, whereas
higher concentrations of Aβ induces the pathophysiologi-
cal activation of ERK in glial cells.
Earlier studies demonstrated that treatment of acute hip-
pocampal slices with a superoxide-generating system
causes ERK phosphorylation [38]. The involvement of
ERK signaling in synaptic plasticity and memory function
has been studied intensely [39] and several studies have
demonstrated an important role for NADPH oxidase and
ROS in synaptic plasticity and learning and memory
[22,40]. Moreover, N-methyl-D-aspartate (NMDA) recep-
tor-dependent activation of ERK in the hippocampus is
mediated by NADPH oxidase [40]. Our findings strongly
suggest that both Aβ and nicotine treatments trigger an
increase in ERK phosphorylation in hippocampal pyram-
idal neurons via NADPH oxidase (Figure 2) and are in
agreement with a previous study in cortical neurons [28].
There also is evidence that neutrophils stimulated with Aβ
fragments (25-35) at micromolar concentrations activate
ERK, resulting in the activation of NADPH oxidase to pro-
duce superoxide [41]. This apparent difference in signal-
ing modules could be due to the cell type, Aβ peptide
solution, or the Aβ concentration and time of incubation
used. Regardless, there is extensive evidence that superox-
ide produced by NADPH oxidase triggers ERK activation
during both physiological and pathophysiological condi-
tions [42-44]. An involvement of NADPH oxidase in ERK-
mediated signaling after nicotine treatment has not been
studied extensively. However, it was shown that in non-
neuronal cells nicotine can modulate cell function via
both NADPH oxidase and ERK [45]. Taken together, our
results are in agreement with others and point to a signif-
icant role for NADPH oxidase in ERK activation by either
Aβ or nicotine.
In agreement with previous studies [4] we found that
nanomolar concentrations of MLA inhibited the increase
in active ERK after Aβ treatment (Figure 4). The impor-
tance of the interaction of Aβ with α7nAChRs during both
normal synaptic plasticity and pathologic conditions such
as AD is well recognized [46], but further studies are nec-
essary to increase our understanding of the signaling cas-
cades mediating these processes.
At the present time the subcellular localization of NADPH
oxidase involved in the Aβ/ERK signaling pathway in the
hippocampus is not clear. Our findings indicate that Aβ
treatment causes the activation of ERK in pyramidal neu-
ron cell bodies and dendrites and we have previously
shown a synaptic localization of NADPH oxidase in the
hippocampus [20]. One possible scenario is that Aβ
causes the activation of NADPH oxidase postsynaptically
and that the production of ROS causes the activation of
ERK in both cell bodies and dendritic compartments.
Another possibility is that NADPH oxidase is present pre-
synaptically and that after Aβ treatment, the superoxide
that is produced travels trans-synaptically, leading to the
activation of ERK in postsynaptic pyramidal neurons.
These possibilities remain to be examined.
Whether the involvement of the α7nChR in the Aβ-
induced ERK activation is upstream of the NADPH oxi-
dase activation is still unclear. α7nChRs have been shown
to be present in both presynaptic and postsynaptic com-
partments of pyramidal neurons, as well as in GABAergic
interneurons [47-49]. It has been suggested that nAChRs
at presynaptic locations on excitatory neurons couldPage 7 of 10
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nicotinic receptor activation is indeed upstream to
NADPH oxidase activation, one can speculate that Aβ
binds to presynaptic nAChRs, enhancing release of gluta-
mate, which would lead to increases in postsynaptic cal-
cium followed by activation of NADPH oxidase and ERK.
Another possibility is that Aβ binds to nicotinic receptors
in the postsynaptic neuron causing depolarization,
NADPH oxidase activation, and subsequent ERK activa-
tion. More studies will be necessary to directly investigate
which additional mechanisms are involved in the Aβ-
induced ERK activation.
Conclusion
Our findings indicate that NADPH oxidase-dependent
redox signaling is required for Aβ-induced activation of
ERK in hippocampal neurons. These observations expand
our understanding of the regulation and signaling cas-
cades activated by Aβ and provide insight about the sign-
aling cascades that might be triggered during the early
stages of Alzheimer's disease.
Methods
Hippocampal slice cultures and treatment
Slice cultures were prepared from P7 Sprague-Dawley rat
pups and maintained in culture according to the method
of Stoppini et. al. [50]. On the seventh day of culture, hip-
pocampal slices were treated in the presence or absence of
the NADPH inhibitors apocynin (100 μM, Sigma/Aldrich,
St. Louis, MO) for 30 min, or diphenyleneiodomium
(DPI 10 μM, Calbiochem, San Diego, CA) for 1 hr and the
α7nAChR inhibitor methyllycaconitine (MLA 10 nM,
Tocris, Ellisville, MO) for 30 min. Media was removed
and replaced with media containing the inhibitors in the
presence or absence of Aβ1-42 (100 nM; Calbiochem, San
Diego, CA), or nicotine (500 nM; Sigma/Aldrich, St.
Louis, MO) for 5 or 10 min, respectively.
Aβ preparation: Stock solution of synthetic rat Aβ1-42
(Calbiochem, San Diego, CA) was prepared at 100 mM in
200 mM HEPES, pH 8.0. The solution was gently agitated
for ~ 30 min, aliquoted, and stored at -80°C. As previ-
ously published this method of Aβ preparation forms oli-
gomers and not high molecular weight or fibrillar
aggregate forms [3].
Immunocytochemistry
After treatment with media in the presence or absence of
the inhibitors and either Aβ (100 nM, 5 min) or nicotine
(500 nM, 10 min) hippocampal slice cultures were fixed
in 4% paraformaldehyde and 4% sucrose overnight at
4°C. Then the cultures were washed in phosphate buffer
solution (PBS), permeabilized with 0.1% Triton X-100
and blocked with 4% normal goat serum for 30 min each.
Slice cultures were incubated in phospho-ERK1/2
([1:1000], Cell Signaling Technology Inc., Danvers, MA),
NeuN (neuron-specific nuclear protein, [1:100], Milli-
pore/Chemicon, Billerica, MA), MAP2 (microtubulin
associated protein, [1:1000], Cell Signaling Technology
Inc., Danvers, MA), GFAP (glial fibrillary acidic protein,
[1:100], (Invitrogen/Molecular Probes, Carlsbad, CA),
isolectin GS-IB4 (IB4, [1:1000], Invitrogen/Molecular
Probes, Carlsbad, CA), and glutamic acid decarboxylase
(GAD67, Millipore/Chemicon, Billerica, MA) overnight,
rinsed with PBS and incubated for 2 hr with secondary
antibodies Alexa 488 [1:200], and Alexa 594, [1:200], Inv-
itrogen/Molecular Probes, Carlsbad, CA). Slices were
washed in PBS, mounted on coverslips and analyzed
using a Zeiss LSM 510 meta confocal microscope.
Western blot hybridization
Hippocampal slices were homogenized in 10 mM HEPES,
1 mM EGTA, 1 mM EDTA, 150 mM NaCl, 50 mM NaF,
and 10 mM Na4P2O7 supplemented with protease inhibi-
tors, and phosphatase inhibitors (PI-I, PI-II, Sigma). The
homogenate was sonicated and equivalent amounts of
protein from each sample were resolved via 10% SDS-
PAGE, transferred to Immobilon membranes, and incu-
bated in I-Block (Applied Biosystems/Tropix, Foster City,
CA). Blots then were incubated with primary antibodies
phospho-ERK2 (1:3000), or ERK1/2 (1:3000) for 1 hr fol-
lowed by horseradish peroxidase-linked secondary anti-
body and developed using enhanced chemiluminescence
(Millipore/Amersham, Billerica, MA). Densitometric
analyses of immunoreactivity were conducted using NIH
image software.
Statistical analysis
Statistical analyses were performed using a one-way
ANOVA with Tukey's test for multiple comparisons to
determine significant differences between control and
treatment groups (control versus Aβ or nicotine; Aβ versus
Aβ + drug; nicotine versus nicotine + drug). A p value of
less than 0.05 was considered statistically significant. For
Western blots analyses the results described represent at
least n = 3 and each experimental condition contained
replicates of between 6 - 8 slices.
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